CRC Screening Project 1

Gastroenterology & Hepatology

ARTICLES | VOLUME 6, ISSUE 4, P304-314, APRIL 01, 2021

Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study

Lucie de Jonge, MSc 🙎 † 🖾 • Joachim Worthington, PhD † • Francine van Wifferen, MSc • Nicolas Iragorri, MSc •

Elisabeth F P Peterse, PhD • Jie-Bin Lew, PhD • Marjolein J E Greuter, PhD • Heather A Smith, PhD •

Eleonora Feletto, PhD • Jean H E Yong, MASc • Prof Karen Canfell, PhD • Veerle M H Coupé, PhD •

Iris Lansdorp-Vogelaar, PhD • on behalf of the COVID-19 and Cancer Global Modelling Consortium working group 2 •

Show less . Show footnotes

Published: February 03, 2021 • DOI: https://doi.org/10.1016/S2468-1253(21)00003-0















CCGMC WG2 - project 1

Aim: to estimate the impact of hypothetical disruptions to organised FIT-based colorectal cancer screening programmes on long-term colorectal cancer incidence and mortality.

- A short-term disruption to colorectal cancer screening is projected to have a modest long-term effect on colorectal cancer deaths.
- It is crucial that catch-up screening is provided to mitigate the impact on colorectal cancer burden.

Reference: de Jonge L*, Worthington J*, van Wifferen F, Iragorri N, Peterse EF, Lew JB, Greuter MJ, Smith HA, Feletto E, Yong JH, Canfell K. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. The Lancet Gastroenterology & Hepatology. 2021 Apr 1;6(4):304-14. (*joint first authors)











CRC screening Project 2

Aim: to evaluate strategies that clear the CRC screening backlog due to the COVID-19 pandemic using limited colonoscopy resources, including:

- Performing catch-up screening at regular FIT threshold in 6, 12 & 24 months
- Performing catch-up screening at increased FIT threshold in 6, 12 & 24 months
 - Netherlands: 47, 50, 55, 60, 70, 80 μg HB/g faeces
 - Canada & Australia: 20, 25, 30, 40, 50, 60 μg HB/g faeces

Using 4 microsimulation models (ASCCA, MISCAN-Colon, OncoSim, Policy1-Bowel) to evaluate the programs in the Netherlands, Canada and Australia.










Project 2 – ASCCA results

A. ASCCA - the Netherlands







Organization

50 🔳 55



70 80







Conclusions

- Optimal strategies are setting-specific, however:
 - Catch-up of screening for people who were affected by a 3month disruption over a 24-month period could avert most excess CRC-related deaths
 - This would require a small increase in diagnostic colonoscopy demand after a positive FIT.
 - Increasing the FIT threshold slightly over a long recovery period could ease the pressure on colonoscopy resources.









CRC screening Project 3

- Extension of <u>Project 1</u>, which used hypothetical screening pauses in the Netherlands, Australia & Canada
- Planning phase:
 - Extending to other countries with comparable FIT-based screening programs
 - Scoping of available real-world screening data (ICSN survey, information from local programs)
 - Additional outputs including the economic impact of the disruption







